SELLAS Life Sciences Group Inc

SLSNASDAQ · USD
11.37USD-0.12 (-1.05%)
2210

SELLAS Life Sciences Group Inc (SLS) Straddle

SLS straddle scan found 253 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 70.7%.

Read more

Trading a SLS straddle lets you take a pure volatility position on SELLAS Life Sciences Group Inc without committing to a direction. SELLAS Life Sciences Group Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate SLS straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on SLS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when SELLAS Life Sciences Group Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the SLS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.

It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the SLS straddle is the cleanest expression of that view. Our scanner prices every SLS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a SLS straddle into a catalyst or short a SLS straddle to harvest decay, the options straddle setups that matter are all in one place.

Jan 19, 202925.00$24.3585478%70.7%$49.35$0.650
Jan 21, 202830.00$27.5549078%69.1%$57.55$2.453,127
Apr 16, 202728.00$22.3021078%63.6%$50.30$5.700
Sep 25, 202611.00$1.40778%63.3%$12.40$9.6077
Apr 16, 202727.00$21.5321078%62.7%$48.53$5.480
Apr 16, 202730.00$24.4021078%62.6%$54.40$5.607
Apr 16, 202726.00$20.9021078%61.0%$46.90$5.100
Apr 16, 202725.00$19.9821078%60.9%$44.98$5.030
Sep 25, 202611.50$1.58778%60.8%$13.08$9.93241
Sep 25, 202612.50$1.85778%60.7%$14.35$10.65217

As of September 18, 2026

Find the right straddle before volatility moves

Track SLS straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial